New strategies for treating Venous Thromboembolism
Detailed estimates of VTE events are hard to obtain because they are very difficult to diagnose and often clinically silent. However, VTE is preventable and evidence-based prevention strategies can help stop the development of clots in 'at-risk' individuals.
Boston Scientific seeks to make minimally-invasive, interventional treatments the new standard of care for treating intermediate-high-risk Pulmonary Embolism and DVT.
Help patients with Pulmonary Embolism get better faster, for longer
Pulmonary embolism (PE) directly causes or contributes to 15% of hospital deaths.1 Ultrasound-assisted, catheter-based thrombolysis opens new treatment options between anticoagulation and systemic thrombolysis. Learn more >
Visit the Learning Centre to access case studies, expert videos, learning programme overviews, a bibliography of clinical articles and more.
New studies, new campaigns, new training modules…Visit What’s New to discover the latest findings and activities in this field.
Pulmonary embolism (PE) usually originates as deep vein thrombosis (DVT) – clot formation in the deep veins of the leg, groin or arm. PE occurs when the clot travels in the circulation and lodges in the lungs. 50% of patients who have proximal DVT (clot in the popliteal, femoral, or iliac veins) are at risk of PE2, and 79% of patients presenting with PE have evidence of DVT.3,4
Learn more about Pulmonary Embolism and its symptoms.
Expand your education about endovascular interventions